Detalhe da pesquisa
1.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Br J Haematol
; 200(2): 175-186, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214090
Mostrar mais
Texto completo
2.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol
; 194(2): 393-402, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195988
3.
Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cancer
; 126(15): 3438-3447, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32459375
4.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med
; 376(10): 917-927, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273028
5.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood
; 132(4): 393-404, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567798
6.
Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
Br J Haematol
; 186(1): 54-59, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30864168
7.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood
; 129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
8.
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Br J Haematol
; 182(6): 807-815, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984825
9.
Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells.
Biochem Biophys Res Commun
; 498(4): 715-722, 2018 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29550484
10.
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Blood
; 127(6): 703-12, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603839
11.
Age-related health care disparities in multiple myeloma.
Hematol Oncol
; 36(1): 224-231, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28429426
12.
Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Cancer
; 123(18): 3609-3616, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28497898
13.
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
Cancer
; 123(10): 1791-1799, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28026860
14.
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Haematologica
; 102(8): 1368-1377, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28522576
15.
The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
J Pathol
; 240(3): 262-268, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27513300
16.
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.
Health Qual Life Outcomes
; 15(1): 204, 2017 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29047379
17.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(5): 612-21, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083332
18.
Reply to Comment on low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cancer
; 127(6): 976-978, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33095912
19.
Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples.
Eur J Immunol
; 45(7): 1926-33, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25903796
20.
Ponatinib and platelets a conflict in CML.
Blood
; 133(14): 1520-1521, 2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948369